Transperineal vs. Transrectal MRI-targeted Prostate Biopsy
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
Approximately one million transrectal prostate biopsies are performed annually in the U.S.,
and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of
rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach
under local anesthesia compared to the standard practice transrectal MRI-targeted prostate
biopsy has a much lower risk of infection, comparable pain/discomfort and may improve
detection of prostate cancer.
This randomized controlled trial will be the first prospective study to evaluate in-office
transperineal MRI targeted prostate biopsy.
The investigators hypothesize that a transperineal MRI-targeted biopsy approach under local
anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a
much lower risk of infection, comparable pain/discomfort and may improve detection of
prostate cancer.